Jaguar Health Q2 2026: Net Loss Widens to $12.7M, NDA for MVID Targeted for Q2 2027
JAGX sits 27% above its 52-week low of $0.725.
Summary
Jaguar Health's Q2 2026 loss widened to $12.7 million on sharply lower revenue, while the company advanced its crofelemer program for rare intestinal failure diseases with NDA submission targeted for Q2 2027.
Key Events · Earnings and Guidance · JAGX
-
Q2 Net Loss Widens to $12.7M
Net loss attributable to common stockholders increased 22% year-over-year to $12.7 million, driven by higher interest expense, fair value losses on warrants, and debt extinguishment costs.
-
Revenue Plunges 59% to $1.2M
Total revenue fell to $1.2 million from $2.98 million a year ago, primarily due to the licensing of Mytesi and Canalevia-CA1 to Future Pak, which shifted U.S. sales away from Jaguar.
-
Going Concern and Cash Crunch
The company has a going concern warning and only $3.8 million in cash as of the latest 10-Q, raising doubts about its ability to fund operations through the NDA submission timeline.
-
Crofelemer NDA Submission Targeted for Q2 2027
Jaguar expects the clinical package for crofelemer for MVID to be ready by end of 2026, allowing NDA submission in Q2 2027, with recent ESPGHAN data showing up to 48% reduction in parenteral support.
Analysis · JAGX · Life Sciences
Jaguar Health reported Q2 2026 results with a net loss of $12.7 million, up 22% year-over-year, driven by higher interest expense, fair value losses on warrants, and debt extinguishment costs. Revenue fell 59% to $1.2 million following the licensing of Mytesi and Canalevia-CA1 to Future Pak. The company highlighted progress on crofelemer for rare intestinal failure diseases, with NDA submission for MVID expected in Q2 2027. This comes amid a going concern warning and only $3.8 million in cash as of the latest 10-Q, underscoring the company's precarious financial position.
At the time of this filing, JAGX was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.73 to $85.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.